

PATENT

Rec'd PCT/PTO 04 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Parker et al.

Examiner:

Art Unit:

Serial No.: **09/719,758**

Filed: **December 14, 2000**

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
1st Class Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

NOV. 12, 2001

Date of Deposit

Signature *A. H. Daniels*

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Karen Krupen

Karen I. Krupen, Reg. No. 34,647
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626

Aventis Docket No. ST98017A US